BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week...

Related Keywords

California ,United States ,Stacy Lindborg ,John Mullaly ,National Ms Society ,Motor Neuron Diseases Gordon Research Conference ,California Institute For Regenerative Medicine ,European Medicines Agency ,Prnewswire Brainstorm Cell Therapeutics Inc ,Lifesci Advisors ,Nasdaq ,Brainstorm Cell Therapeutics Inc ,Drug Administration ,Gordon Research Conference ,Gordon Research ,Storm Cell Therapeutics ,Related Motor Neuron Diseases Gordon Research ,Nurown Phase ,Rating Scale ,Floor Effect ,Brainstorm Cell Therapeutics ,Orphan Drug ,California Institute ,Regenerative Medicine ,Harbor Statement ,Sci Advisors ,